Cerebrospinal Fluid Chloride Is Associated with Disease Activity of Relapsing–Remitting Multiple Sclerosis: A Retrospective Cohort Study

: Background: Blood-brain barrier dysfunction in active multiple sclerosis (MS) lesions leads to pathological changes in the cerebrospinal fluid (CSF). This study aimed to investigate the possible association between routine CSF findings, especially CSF chloride, at the time of the first lumbar puncture and the relapse risk and disability progression of relapsing–remitting MS (RRMS). Methods: This retrospective study included 77 patients with RRMS at the MS Center of our institution from January 2012 to December 2020. The Anderson and Gill (AG) model and Spearman correlation analysis were used to explore predictors of relapse and disability during follow-up. Results: In the multivariate AG model, patients with elevated CSF chloride level (hazard ratio [HR], 1.1; 95% confidence interval [CI]: 1.06–1.22; p = 0.001) had a high risk of MS relapse. Using median values of CSF chloride (123.2 mmol/L) as a cut-off, patients with CSF chloride level ≥ 123.2 mmol/L had a 120% increased relapse risk compared with those with CSF chloride level < 123.2 mmol/L (HR = 2.20; 95% CI: 1.19–4.05; p = 0.012). Conclusions: Elevated CSF chloride levels might be a biologically unfavorable predictive factor for disease relapse in RRMS.

[1]  M. Süße,et al.  Kappa Free Light Chains in Cerebrospinal Fluid in Inflammatory and Non-Inflammatory Neurological Diseases , 2022, Brain sciences.

[2]  Zhuoyi Liu,et al.  Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. , 2021, Autoimmunity reviews.

[3]  J. Nicholas,et al.  Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis , 2020, Advances in Therapy.

[4]  E. Leray,et al.  Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.

[5]  S. Hauser,et al.  Treatment of Multiple Sclerosis: A Review. , 2020, The American journal of medicine.

[6]  K. Rejdak,et al.  Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors. , 2020, Neurologia i neurochirurgia polska.

[7]  B. Zeydan,et al.  Impact of Age on Multiple Sclerosis Disease Activity and Progression , 2020, Current Neurology and Neuroscience Reports.

[8]  A. Chan,et al.  Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study , 2020, Therapeutic Advances in Neurological Disorders.

[9]  F. Benninger,et al.  Does CSF pleocytosis have a predictive value for disease course in MS? , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[10]  V. Tomassini,et al.  Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis , 2019, JAMA neurology.

[11]  Xavier Montalban,et al.  Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis , 2019, Nature Reviews Neurology.

[12]  Robert C Reiner,et al.  Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[13]  M. Comabella,et al.  Biomarkers in Multiple Sclerosis. , 2019, Cold Spring Harbor perspectives in medicine.

[14]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[15]  G. Pardo,et al.  The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations , 2017, Journal of Neurology.

[16]  Marc Debouverie,et al.  Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study , 2017, Neuroepidemiology.

[17]  K. Staley,et al.  Chloride Dysregulation, Seizures, and Cerebral Edema: A Relationship with Therapeutic Potential , 2017, Trends in Neurosciences.

[18]  L. Vinay,et al.  Chloride Regulation: A Dynamic Equilibrium Crucial for Synaptic Inhibition , 2016, Neuron.

[19]  D. Centonze,et al.  Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression , 2016, Journal of Neuroinflammation.

[20]  Jianwen Cai,et al.  Modelling recurrent events: a tutorial for analysis in epidemiology. , 2015, International journal of epidemiology.

[21]  B. Casanova,et al.  Perturbed Glucose Metabolism: Insights into Multiple Sclerosis Pathogenesis , 2014, Front. Neurol..

[22]  Gabriele Deidda,et al.  Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives , 2014, Front. Cell. Neurosci..

[23]  W. Boron,et al.  Intracellular pH regulation by acid-base transporters in mammalian neurons , 2014, Front. Physiol..

[24]  Xusheng Huang,et al.  Significance of chloride contents in cerebrospinal fluid and plasma and their ratio in early diagnosis and differential diagnosis of central nervous system infections , 2014 .

[25]  J. Lechner-Scott,et al.  Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. , 2013, Brain : a journal of neurology.

[26]  M. Kamermans,et al.  Brain white matter oedema due to ClC-2 chloride channel deficiency: an observational analytical study , 2013, The Lancet Neurology.

[27]  G. Pawelec Hallmarks of human “immunosenescence”: adaptation or dysregulation? , 2012, Immunity & Ageing.

[28]  S. Skaper Ion channels on microglia: therapeutic targets for neuroprotection. , 2011, CNS & neurological disorders drug targets.

[29]  T. Freund,et al.  Relationship between neuronal vulnerability and potassium-chloride cotransporter 2 immunoreactivity in hippocampus following transient forebrain ischemia , 2008, Neuroscience.

[30]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[31]  A. Rovira,et al.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.

[32]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[33]  F. Galeffi,et al.  Changes in Intracellular Chloride after Oxygen–Glucose Deprivation of the Adult Hippocampal Slice: Effect of Diazepam , 2004, The Journal of Neuroscience.

[34]  Dean A Seehusen,et al.  Cerebrospinal fluid analysis. , 2003, American family physician.

[35]  Ryozo Ohno,et al.  [Cerebrospinal fluid in multiple sclerosis]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[36]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[37]  E. Schoen Spinal fluid chloride: a test 40 years past its time. , 1984, JAMA.

[38]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[39]  T. Alsaadi,et al.  Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. , 2019, Multiple sclerosis and related disorders.

[40]  G. Feng,et al.  The Chloride Transporter Na+-K+-Cl− Cotransporter Isoform-1 Contributes to Intracellular Chloride Increases after In Vitro Ischemia , 2006, The Journal of Neuroscience.

[41]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.